| Recruiting | THE MALABSORPTION BLOOD TEST TRIAL WILL HELP DETERMINE THE BENEFITS OF PANCREATIC ENZYME REPLACEMENT THERAPY I NCT07418593 | Anna Evans Phillips | Phase 4 |
| Not Yet Recruiting | A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects NCT07285863 | Mayo Clinic | Phase 4 |
| Not Yet Recruiting | Fatty Liver and Pancreatic Steatosis NCT06757348 | Maria Marta Piskorz | — |
| Not Yet Recruiting | Exocrine Pancreatic Insufficiency and Functional Dyspepsia NCT06756503 | Maria Marta Piskorz | — |
| Recruiting | Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ NCT05710315 | Inova Health Care Services | N/A |
| Recruiting | Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform NCT06999954 | Shwachman-Diamond Syndrome Alliance Inc | — |
| Recruiting | Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency NCT06477159 | Ohio State University | Phase 4 |
| Completed | Phase 1 Study to Assess Safety and Efficacy of ANG003 NCT06052293 | Anagram Therapeutics, Inc. | Phase 1 |
| Completed | AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients NCT06278272 | Changhai Hospital | — |
| Completed | Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis NCT05719311 | Entero Therapeutics | Phase 2 |
| Unknown | Exocrine Pancreatic Insufficiency After Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy NCT05480241 | Unidade Local de Saúde de Coimbra, EPE | N/A |
| Completed | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Exocrine Pancreatic Dysfunction in Type 1 Diabe NCT05385211 | Ciusss de L'Est de l'Île de Montréal | — |
| Unknown | Endotherapy for Painless Chronic Pancreatitis NCT05261997 | Changhai Hospital | N/A |
| Completed | Oral CDX-7108 in Healthy Adults and EPI Subjects NCT05082051 | Société des Produits Nestlé (SPN) | Phase 1 |
| Recruiting | The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding NCT05112328 | Seoul National University Hospital | N/A |
| Unknown | Registry of Pancreatic Exocrine Insufficiency. NCT05450627 | Hospital Clinico Universitario de Santiago | — |
| Completed | BÜHLMANN FPELA in the Diagnosis of Exocrine Pancreatic Insufficiency NCT04548778 | Bühlmann Laboratories AG | — |
| Suspended | Role of Pancreatic Exocrine Secretion in Weight Gain After Pancreas Transplantation NCT04690738 | Rush University Medical Center | — |
| Unknown | Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresect NCT04112836 | Moscow Clinical Scientific Center | — |
| Completed | Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis NCT04966897 | GlycosBio, Inc. | N/A |
| Completed | Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis NCT03236038 | Corporacion Parc Tauli | — |
| Unknown | RESULT: Reliable, Emergent Solution Using Liprotamase Treatment NCT03051490 | Anthera Pharmaceuticals | Phase 3 |
| Completed | EASY: Extended Access to Sollpura Over Years NCT02823964 | Anthera Pharmaceuticals | Phase 4 |
| Completed | SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis NCT02734810 | Anthera Pharmaceuticals | Phase 3 |
| Completed | Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb) NCT02598128 | Alcresta Therapeutics, Inc. | N/A |
| Completed | Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating NCT03407534 | Baylor College of Medicine | — |
| Completed | Pancreatic Exocrine Insufficiency in Acute Pancreatitis NCT02563080 | Helsinki University Central Hospital | — |
| Completed | SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosi NCT02279498 | Anthera Pharmaceuticals | Phase 3 |
| Completed | A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes NCT02370537 | AstraZeneca | Phase 2 |
| Completed | Baby Observational and Nutritional Study NCT01424696 | Seattle Children's Hospital | — |
| Completed | Enzyme Suppletion in Exocrine Pancreatic Dysfunction NCT01430234 | Foundation for Liver Research | Phase 4 |
| Completed | Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency NCT01427725 | Mylan Inc. | — |
| Completed | Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cysti NCT01427712 | Mylan Inc. | — |
| Completed | Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency NCT01327703 | Forest Laboratories | Phase 4 |
| Recruiting | Investigating Predictive Factors of Diabetes Occurence After Duodenalpancreatectomy NCT02175459 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Completed | PR-018: An Open-Label, Safety Extension of Study PR-011 NCT01131507 | Forest Laboratories | Phase 4 |
| Completed | A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of NCT01100606 | Forest Laboratories | Phase 4 |
| Withdrawn | Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients NCT00663975 | Digestive Care, Inc. | N/A |
| Completed | Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency NCT00743483 | Swedish Orphan Biovitrum | Phase 2 |
| Completed | A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic NCT00662675 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
| Terminated | Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control NCT00744250 | Digestive Care, Inc. | Phase 4 |
| Completed | A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insuffic NCT00676702 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 |
| Completed | An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exoc NCT00559052 | Axcan Pharma | Phase 2 |
| Completed | A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two NCT00788593 | Forest Laboratories | Phase 3 |
| Terminated | Phase III ALTU-135 CP Safety Trial NCT00500084 | Anthera Pharmaceuticals | Phase 3 |
| Completed | Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea NCT00559364 | Forest Laboratories | Phase 3 |
| Completed | Open-Label Phase III Long-Term Safety Trial of Liprotamase NCT00449904 | Anthera Pharmaceuticals | Phase 3 |
| Completed | Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency NCT00449878 | Anthera Pharmaceuticals | Phase 3 |
| Terminated | Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum) NCT00749099 | Digestive Care, Inc. | N/A |
| Completed | Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic I NCT00408317 | Forest Laboratories | Phase 3 |
| Completed | Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insu NCT00981214 | Forest Laboratories | Phase 3 |
| Completed | Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants Wit NCT00297167 | Forest Laboratories | Phase 3 |